Loading...
From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (part 2/5)
Leong, Darryl P. McMurray, John J. V. Joseph, Philip G. Yusuf, Salim
Leong, Darryl P.
McMurray, John J. V.
Joseph, Philip G.
Yusuf, Salim
Abstract
The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies.
Keywords
ACE-I, ARB, ARNI, coronary disease, heart failure
Date
2019
Type
Journal article
Journal
Journal of the American College of Cardiology
Book
Volume
74
Issue
5
Page Range
683-698
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled